Sonoma Pharmaceuticals Inc (SNOA, Financial) files its latest 10-K with SEC for the fiscal year ended on March 31, 2018. Sonoma Pharmaceuticals Inc is a speciality pharmaceutical company. It develops,identifies and commercialises therapies for dermatologic diseases. Sonoma Pharmaceuticals Inc has a market cap of $15.750 million; its shares were traded at around $2.55 with and P/S ratio of 0.65.
For the last quarter Sonoma Pharmaceuticals Inc reported a revenue of $3.66 million, compared with the revenue of $4.03 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $16.7 million, an increase of 29.9% from last year. For the last five years Sonoma Pharmaceuticals Inc had an average revenue decline of 0.6% a year.
The reported loss per diluted share was $3.16 for the year, compared with the earnings per share of $-3.09 in the previous year. The Sonoma Pharmaceuticals Inc had an operating margin of -85.18%, compared with the operating margin of -101.16% a year before. The 10-year historical median operating margin of Sonoma Pharmaceuticals Inc is -89.05%. The profitability rank of the company is 1 (out of 10).
At the end of the fiscal year, Sonoma Pharmaceuticals Inc has the cash and cash equivalents of $10.1 million, compared with $17.5 million in the previous year. The long term debt was $0.18 million, compared with $0.21 million in the previous year. Sonoma Pharmaceuticals Inc has a financial strength rank of 5 (out of 10).
At the current stock price of $2.55, Sonoma Pharmaceuticals Inc is traded at 66% discount to its historical median P/S valuation band of $7.51. The P/S ratio of the stock is 0.65, while the historical median P/S ratio is 1.91. The stock lost 62.27% during the past 12 months.
For the complete 20-year historical financial data of SNOA, click here.
